<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H6E9029C2DCF74D99BD649E075809897E" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>116 HR 5402 IH: Protecting America’s Life Saving Medicines Act of 2019</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2019-12-11</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">116th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5402</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20191211">December 11, 2019</action-date><action-desc><sponsor name-id="G000583">Mr. Gottheimer</sponsor> (for himself and <cosponsor name-id="U000031">Mr. Upton</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name>, and in addition to the Committee on <committee-name committee-id="HIF00">Energy and Commerce</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and
			 Drugs, to conduct a study on high-risk, high-reward drugs, and for other
			 purposes.</official-title></form>
	<legis-body id="H5C0349A618054961BFAD310580A78F47" style="OLC">
 <section id="H1C563936A3C54E8FB0D1F7CE85197E86" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Protecting America’s Life Saving Medicines Act of 2019</short-title></quote>.</text> </section><section id="HB7B51F98D55B4E48B66DF81AF0838F0B"><enum>2.</enum><header>Study on high-risk, high-reward drugs</header> <subsection id="H1A2838DB0E854EC581B67D9E465D2C59"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 180 days after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall conduct a study to determine which of the drugs that are being tested (as of such date of enactment) under subsection (i) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) are unlikely to be approved under subsection (c) of such section, but would, if approved, address an unmet medical need for the treatment of a serious or life-threatening disease or condition or a rare disease or condition.</text>
 </subsection><subsection id="H6F80984F84484B07856433AC0BE982EF"><enum>(b)</enum><header>Submission to Treasury</header><text>Not later than 180 days after the completion of the study under subsection (a), the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall transmit to the Secretary of the Treasury (or the Secretary’s delegate) a list of the drugs that the Secretary of Health and Human Services determines meets the criteria specified in subsection (a).</text>
			</subsection></section><section id="HB1DCA7A9855745B6A94C4F5427B43B59"><enum>3.</enum><header>Credit for clinical testing expenses for certain high-risk, high-reward drugs</header>
 <subsection commented="no" id="H5FE70ED6E4744660B145E153E2F41E59"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Subpart D of part IV of subchapter A of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/1">chapter 1</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:</text>
				<quoted-block display-inline="no-display-inline" id="HB8A7CDD56CE647B998A4A27B174E4727" style="OLC">
					<section commented="no" id="H541F8DAD94614A4E98B0C81478C6C36C"><enum>45T.</enum><header>Clinical testing expenses for certain high-risk, high-reward drugs</header>
 <subsection id="H34B60AF08B844C5A98C0714B69F5A051"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">For purposes of section 38, the credit determined under this section for the taxable year is an amount equal to 25 percent of the qualified clinical testing expenses for the taxable year.</text>
 </subsection><subsection id="H1029FCECDE1745BEBADD989C7BA078F7"><enum>(b)</enum><header>Qualified clinical testing expenses</header><text>For purposes of this section—</text> <paragraph id="H6EA55CD7ABBE40218BB151DADD9D96D7"><enum>(1)</enum><header>Qualified clinical testing expenses</header> <subparagraph id="HD930F544B10549D08DF93B3768192498"><enum>(A)</enum><header>In general</header><text>Except as otherwise provided in this paragraph, the term <term>qualified clinical testing expenses</term> means the amounts which are paid or incurred by the taxpayer during the taxable year which would be described in subsection (b) of section 41 if such subsection were applied with the modifications set forth in subparagraph (B).</text>
 </subparagraph><subparagraph id="H6EC730DCB5B54CF0B7D4970F876DCBE0"><enum>(B)</enum><header>Modifications</header><text>For purposes of subparagraph (A), subsection (b) of section 41 shall be applied—</text> <clause id="HB4AA7768243342A9A458E619635BF5B1"><enum>(i)</enum><text>by substituting <quote>clinical testing</quote> for <quote>qualified research</quote> each place it appears in paragraphs (2) and (3) of such subsection, and</text>
 </clause><clause id="HAFC6B3BC61E7497884A5C12E7FF7B028"><enum>(ii)</enum><text>by substituting <quote>100 percent</quote> for <quote>65 percent</quote> in paragraph (3)(A) of such subsection.</text> </clause></subparagraph><subparagraph id="H64545B29BFD64DEC9D7BAB6E9E037DC6"><enum>(C)</enum><header>Exclusion for amounts funded by grants, etc</header><text>The term <term>qualified clinical testing expenses</term> shall not include any amount to the extent such amount is funded by any grant, contract, or otherwise by another person (or any governmental entity).</text>
 </subparagraph></paragraph><paragraph id="H89D93B5ADC9D4F02BE3E0CF2B4C0BF1E"><enum>(2)</enum><header>Clinical testing</header><text>The term <term>clinical testing</term> means any human clinical testing—</text> <subparagraph id="H38A2FA7F433647AA81066749E13533BB"><enum>(A)</enum><text>which is carried out with respect to a drug on a list submitted to the Secretary under subsection (b) of the <short-title>Protecting America’s Life Saving Medicines Act of 2019</short-title>,</text>
 </subparagraph><subparagraph commented="no" id="H49CDBB9615B44EA3A733873E68EA5AD7"><enum>(B)</enum><text>which occurs—</text> <clause commented="no" id="H464B9988D89843458BB0B8F36DC4D90F"><enum>(i)</enum><text>after the date such list is so submitted, and</text>
 </clause><clause commented="no" id="HFC80917C34AA4DE284171CCD654D71B2"><enum>(ii)</enum><text>before the date on which an application with respect to such drug is approved under section 505(b) of such Act or, if the drug is a biological product, before the date on which a license for such drug is issued under section 351 of the Public Health Service Act.</text>
									</clause></subparagraph></paragraph></subsection><subsection id="H98CDAE8B8D914EAC9E1B322C1524C040"><enum>(c)</enum><header>Coordination with credit for increasing research expenditures</header>
 <paragraph id="H35145A9A98F34401AAE90CA34BCB2460"><enum>(1)</enum><header>In general</header><text>Except as provided in paragraph (2), any qualified clinical testing expenses for a taxable year to which an election under this section applies shall not be taken into account for purposes of determining the credit allowable under section 41 for such taxable year.</text>
 </paragraph><paragraph id="HE5F0F53C50D144F0A4D6D356E126C714"><enum>(2)</enum><header>Expenses included in determining base period research expenses</header><text>Any qualified clinical testing expenses for any taxable year which are qualified research expenses (within the meaning of section 41(b)) shall be taken into account in determining base period research expenses for purposes of applying section 41 to subsequent taxable years.</text>
							</paragraph></subsection><subsection id="H0FD52A50C4AA4B3D9022750339C457CB"><enum>(d)</enum><header>Special rules</header>
 <paragraph id="HCCF76D76510548A88A7545DA61B7A0F3"><enum>(1)</enum><header>Certain rules made applicable</header><text>Rules similar to the rules of paragraphs (1) and (2) of section 41(f) shall apply for purposes of this section.</text>
 </paragraph><paragraph id="H1C6FE87A27E144638030106D7448CE2F"><enum>(2)</enum><header>Election</header><text>This section shall apply to any taxpayer for any taxable year only if such taxpayer elects (at such time and in such manner as the Secretary may by regulations prescribe) to have this section apply for such taxable year.</text>
							</paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection commented="no" id="HB21353AD98F2408BA89C97B918D061A5"><enum>(b)</enum><header>Credit made part of general business credit</header><text>Subsection (b) of <external-xref legal-doc="usc" parsable-cite="usc/26/38">section 38</external-xref> of the Internal Revenue Code of 1986 is amended by striking <quote>plus</quote> at the end of paragraph (31), by striking the period at the end of paragraph (32) and inserting <quote>, plus</quote>, and by adding at the end the following new paragraph:</text> <quoted-block display-inline="no-display-inline" id="HB18654C2832A49BDB0A67FEE3D2C37ED" style="OLC"> <paragraph commented="no" id="H52D8BABA5DD74445A06DEA8998AB425F"><enum>(33)</enum><text display-inline="yes-display-inline">the credit determined under section 45T.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection commented="no" id="HC9EE7BD398304339938A2F5FA0CE5C71"><enum>(c)</enum><header>Clerical amendment</header><text display-inline="yes-display-inline">The table of sections for subpart D of part IV of subchapter A of chapter 1 of such Code is amended by adding at the end the following new item:</text>
				<toc regeneration="no-regeneration">
					<toc-entry level="section"><quote>Sec. 45T. Clinical testing expenses for certain high-risk, high-reward drugs.</quote>.</toc-entry></toc>
 </subsection><subsection commented="no" id="HB2F9C0C9BBCC4C82931950DE7F63EC99"><enum>(d)</enum><header>Effective date</header><text>The amendments made by this section shall apply to taxable years beginning after the date of the enactment of this Act.</text>
			</subsection></section></legis-body></bill>


